Anti-interleukin 5 therapies such as mepolizumab and benralizumab have been revolutionizing clinical practice in EGPA; therefore, we also discuss current therapies for EGPA, including these biological drugs, in Section 3. Here, IL5 is linked to eosinophilic granulomatosis with polyangiitis.